This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Monitoring testosterone therapy

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Monitoring

After starting testosterone (T) therapy, patients should be evaluated at 3, 6 and 12 months, then annually thereafter, to monitor:

  • serum testosterone - aim for a therapeutic target in the mid to upper range (15-30nmol/L), for an optimal response
  • haematocrit - levels should remain <54%. Dose reductions or preparation changes may be required to keep haematocrit levels within range. If they remain high, consider stopping T therapy and reintroducing it at a lower dose
  • PSA - prostate health should have been assessed via DRE and PSA prior to starting treatment. After initiating T therapy, a PSA increase >1.4ng/mL over a 1-year period, or a PSA velocity >0.4ng/mL/year during sequential measurements over >2 years warrants urological evaluation and more intensive surveillance for prostate cancer thereafter1
  • cardiovascular risk factors - these should also have been assessed prior to staring treatment
  • symptomatic improvement - failure to benefit within a reasonable time frame (defined as 6 months for libido, sexual function, muscle function & improved body fat) should prompt treatment discontinuation and investigation for other causes of the symptoms1

Reference


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.